Celsion Corporation (NASDAQ:CLSN) released its quarterly earnings results on Tuesday. The biotechnology company reported ($0.70) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.56) by ($0.14), Briefing.com reports. Celsion Corporation had a negative net margin of 4,440.60% and a negative return on equity of 276.51%.
Shares of Celsion Corporation (NASDAQ:CLSN) opened at $2.12 on Tuesday. Celsion Corporation has a 1 year low of $1.24 and a 1 year high of $12.60.
Several research firms recently issued reports on CLSN. Maxim Group restated a “hold” rating on shares of Celsion Corporation in a research note on Tuesday, August 15th. ValuEngine upgraded Celsion Corporation from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. Finally, Zacks Investment Research downgraded Celsion Corporation from a “buy” rating to a “hold” rating in a research note on Tuesday, October 17th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $12.63.
About Celsion Corporation
Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).
Receive News & Ratings for Celsion Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion Corporation and related companies with MarketBeat.com's FREE daily email newsletter.